The third paper in the issue of the Journal of Clinical Oncology describes an analysis of a very
rare subset of patients with low - stage disease and amplification of the MYCN oncogene.
Not exact matches
But Yale researchers have identified a
subset of those
patients with a
rare genetic mutation who are living significantly longer than
patients without the mutation.
Overall, despite the dramatic therapeutic advances made elsewhere in the melanoma field, the poor prognosis
of patients with mucosal melanoma mandates continued emphasis on laboratory and clinical research efforts in this
rare subset of disease.